BioGend Therapeutics Co., Ltd. (TPEX: 6733)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
37.00
+0.40 (1.09%)
Sep 11, 2024, 9:20 AM CST
6.02%
Market Cap 4.55B
Revenue (ttm) 133.45M
Net Income (ttm) -120.92M
Shares Out 124.26M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,450
Open 36.90
Previous Close 36.60
Day's Range 36.90 - 37.00
52-Week Range 31.40 - 42.85
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About BioGend Therapeutics

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6733
Full Company Profile

Financial Performance

In 2023, BioGend Therapeutics's revenue was 109.91 million, an increase of 249.51% compared to the previous year's 31.45 million. Losses were -156.33 million, -15.25% less than in 2022.

Financial Statements

News

There is no news available yet.